Sitosterolemia: Diagnostic and Treatment Approach
For patients with tendon xanthomas and elevated LDL-C that is disproportionately mild (or even normal), measure plasma plant sterols (sitosterol, campesterol, stigmasterol) to diagnose sitosterolemia, and confirm with genetic testing for ABCG5/ABCG8 variants. This rare autosomal recessive disorder is frequently misdiagnosed as familial hypercholesterolemia but requires fundamentally different treatment 1.
When to Suspect Sitosterolemia
Maintain high clinical suspicion when you observe:
- Tendon or tuberous xanthomas with LDL-C levels much less extreme than expected (often <300 mg/dL, sometimes even normal) 1
- Hematologic abnormalities: macrothrombocytopenia, hemolytic anemia, stomatocytes on peripheral smear 2, 3
- Poor response to statins but good response to ezetimibe 4
- Additional features: valvular heart disease, splenomegaly, arthralgia, corneal lipid deposits 1, 5
- Premature atherosclerosis in young patients 6
Critical pitfall: The presence of xanthomas does NOT automatically mean familial hypercholesterolemia. Sitosterolemia patients often have xanthomas with only modestly elevated or even normal cholesterol levels 1, 7.
Diagnostic Algorithm
Step 1: Initial Biochemical Testing
- Measure plasma phytosterols (sitosterol, campesterol, stigmasterol) - this is the diagnostic cornerstone 2
- Markedly elevated plant sterol levels confirm the diagnosis biochemically 7
- Check complete blood count looking for macrothrombocytopenia 2
- Review peripheral smear for stomatocytes 3
Step 2: Genetic Confirmation
- Genetic testing for biallelic pathogenic variants in ABCG5 or ABCG8 genes provides definitive diagnosis 1, 2
- This should be performed even if phytosterol levels are diagnostic, as it enables cascade family screening 2
- Consider expanded genetic panels if initial FH genetic testing (LDLR, APOB, PCSK9) is negative in patients with suggestive phenotype 7
Step 3: Cardiovascular Assessment
- Perform CT coronary angiography or other imaging to assess for premature atherosclerosis 7
- Evaluate for valvular heart disease with echocardiography 1
Treatment Strategy
First-line therapy combines strict dietary plant sterol restriction with ezetimibe 10 mg daily 5. This combination is the mainstay of treatment and differs fundamentally from FH management.
Dietary Management (Cornerstone of Therapy)
- Strict low-phytosterol diet restricting plant sterols 5
- Avoid high plant sterol foods (vegetable oils, nuts, seeds, plant sterol-enriched margarines)
- Dietary therapy alone can decrease TC and LDL-C by approximately 50-54% 5
Pharmacologic Therapy
Ezetimibe 10 mg daily is the primary medication 5
Avoid statins as monotherapy - they show poor efficacy in sitosterolemia 4
- Statins may be added if hypercholesterolemia persists despite ezetimibe and diet, but are not first-line
Adjunctive Therapy
- Lipoprotein apheresis can be used in severe, refractory cases 4
Monitoring and Follow-up
Track these parameters:
- Plasma phytosterol levels (sitosterol, campesterol)
- Lipid panel (TC, LDL-C)
- Complete blood count (hemoglobin, platelet count)
- Cardiovascular imaging as clinically indicated
- Symptom resolution (xanthomas, hemolytic anemia, arthralgia)
Expected outcomes: Symptomatic remission occurs in 96% of pediatric and 80% of adult patients with targeted treatment, with significant decreases in lipid and phytosterol levels 5.
Key Clinical Distinctions from Familial Hypercholesterolemia
Sitosterolemia differs critically from FH:
- Genetics: Biallelic ABCG5/ABCG8 variants (not LDLR/APOB/PCSK9) 1
- Pathophysiology: Increased plant sterol absorption/accumulation (not LDL receptor defect) 6
- Treatment response: Excellent response to ezetimibe, poor response to statins 4
- Hematologic features: Macrothrombocytopenia and hemolytic anemia common in sitosterolemia, absent in FH 2, 3
- LDL-C levels: Often less dramatically elevated than expected for degree of xanthomatosis 1
The triad of hematologic abnormalities, good ezetimibe response, and poor statin response should immediately trigger suspicion for sitosterolemia rather than FH 4.